No Data
No Data
HK Stocks Surge | Saisheng Pharmaceutical-B (02171) surges over 13% again, the company has submitted an application to lift the clinical hold, and the commercialization of Saixize is progressing smoothly.
China Resources Pharmaceutical Group Limited-B (02171) rose by over 13%, as of the time of publication, it increased by 12.67%, trading at 5.07 Hong Kong dollars, with a turnover of 28.1184 million Hong Kong dollars.
Express News | CARsgen Therapeutics Holdings Ltd - Application to Request Lifting Clinical-Holds Submitted to FDA
The commercialization of the product is difficult to support alone, and has the identity of the largest bearish event within the year for Science and Economy Pharmaceutical (02171) through the Hong Kong Stock Connect program?
For SciClone Pharmaceuticals-B (02171), the most important milestone event in 2024 is the successful commercialization of the core variety CT053 in March this year. However, the commercialization of the first product did not bring further valuation leap on the secondary market to the company, instead it led to a continuously declining stock price.
CARSGEN-B: INTERIM REPORT 2024
Koji Pharmaceutical - B (02171) fell by 59.60%, now reported at 2.69 yuan, hitting a 52-week low.
As of 11:46, Keji Pharmaceutical - B (02171) fell 59.60% compared to the previous closing price, now at 2.690 yuan, hitting a 52-week low; volume of 3.6526 million shares, with a turnover of 9.8273 million Hong Kong dollars.
CARsgen Therapeutics Holdings Limited's (HKG:2171) Stock Price Dropped 26% Last Week; Individual Investors Would Not Be Happy
No Data
No Data